Parabilis Medicines, Inc.
Clinical-stage biopharmaceutical company developing Helicons, a class of alpha-helical peptides targeting intracellular proteins.
8-KSep 23Latest SEC filing, period to Sep 22
Sep 23Latest story
Sign inSign inClinical-stage biopharmaceutical company developing Helicons, a class of alpha-helical peptides targeting intracellular proteins.